Elite in Peripartum Cardiomyopathy

Mark C. Petrie

126 University Place, G12 8TA, 
Glasgow, SCT, GB 
Elite in Peripartum Cardiomyopathy
126 University Place, G12 8TA, 
Glasgow, SCT, GB 
OverviewLocationsClinical Research

Overview

Mark Petrie practices in Glasgow, United Kingdom. Mr. Petrie is rated as an Elite expert by MediFind in the treatment of Peripartum Cardiomyopathy. His top areas of expertise are Heart Failure, Peripartum Cardiomyopathy, Heart Failure with Preserved Ejection Fraction (HFpEF), Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.

His clinical research consists of co-authoring 420 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Peripartum Cardiomyopathy.

Gender
Male

Locations

126 University Place, G12 8TA, Glasgow, SCT, United Kingdom
Other Locations
Western Infirmary
Glasgow, SCT, United Kingdom
Agamemnon Street, Clydebank, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IV, Registry-based, Randomised, Controlled, Open-label Trial Investigating the Potential for Patiromer-facilitated Use of Higher Doses of MRAs in Addition to Standard Care to Improve Congestion, Well-being, Morbidity and Mortality
A Phase IV, Registry-based, Randomised, Controlled, Open-label Trial Investigating the Potential for Patiromer-facilitated Use of Higher Doses of MRAs in Addition to Standard Care to Improve Congestion, Well-being, Morbidity and Mortality
Enrollment Status: Terminated
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drug: Patiromer
Study Phase: Phase 4
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF)
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF)
Enrollment Status: Completed
Publish Date: September 18, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

420 Total Publications

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.
Journal: ESC heart failure
Published: August 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Petrie's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 38 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile